Anjali Manavalan

Endocrinologist with a particular interest in thyroid disease and female reproductive health.

[NEJM @NEJM]

Sometimes the most caring answer is no. Dr. Michelle Kittleson (@MKIttlesonMD) explains why in a new NEJM Voices blog post. Read the post and sign up for email alerts: https://t.co/DpISki5gmS

[JAMA @JAMA_current]

Clinicians can enhance patient understanding by using numerical data instead of verbal probabilities, consistent denominators, absolute risk comparisons, and clear context for unfamiliar data types.

https://t.co/dcOmkNwtlS

[JAMA @JAMA_current]

Adrenal insufficiency is a syndrome of cortisol deficiency.

This Review summarizes the pathophysiology of adrenal insufficiency and approaches to diagnosis, treatment, and prevention of adrenal crisis.

https://t.co/68Td08HbKV

[Anjali Manavalan @a_manaval]

@dimpi_desai @StanfordEndo 🎊 congratulations

[JAMA @JAMA_current]

In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no additional benefit over semaglutide.

#ESCCongress #WCCardio

https://t.co/WPJZSeylLz

[Dr. Purvi Parwani @purviparwani]

Here’s a 6-point nuanced update from the 2025 ESC/EAS Dyslipidaemia Guidelines #ESCCongress

1.Risk Refinement with Imaging:
#yesCCT #CVimaging
CAC scoring and subclinical atherosclerosis imaging are upgraded to Class IIa, Level B for refining risk in moderate-risk patients or those near treatment thresholds, strengthening their role beyond SCORE2/OP.

2.Expanded Risk Modifiers:
Clinical and demographic factors (e.g., South Asian ethnicity, premature menopause, HIV, OSA, psychosocial stress) and biomarkers (hs-CRP >2 mg/L, Lp(a) >50 mg/dL) are highlighted as enhancers in risk stratification.

3.Stratified Risk Categories:
Markedly elevated CAC now classifies patients into very high-risk, alongside ASCVD, severe CKD, diabetes with organ damage, or SCORE2 ≥20%.

4.LDL-C Treatment Targets:
Intensified LDL goals include <1.4 mmol/L (<55 mg/dL) for very high risk and <1.0 mmol/L (<40 mg/dL) (Class IIb) for “extreme risk” (e.g., recurrent events despite therapy).

5.Therapeutic Innovations:
•Bempedoic acid (Class I) for statin-intolerant patients.
•Evinacumab (Class IIa) for HoFH uncontrolled on maximal therapy.
•High-dose Icosapent ethyl (2 g BID) (Class IIa) for hypertriglyceridaemia with high/very high risk.

6.Acute & Early Intervention:
For ACS hospitalization, intensification of lipid therapy is recommended (Class I), with early high-intensity statin + ezetimibe (Class IIa) in those unlikely to reach LDL-C goals with statin alone.

[NEJM @NEJM]

CONFIDENCE trial: In persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results and Research Summary: https://t.co/4Gf0LboOCp

[Beverly G. Tchang, MD @BevTchangMD]

Stopping medication entirely is not the answer

Alternative dosing regimens for #weightloss maintenance might be

Suggested by mathematical modeling but needs real world data 👉 https://t.co/NLKG3YE1Cu

[Anjali Manavalan @a_manaval]

via @NYTimes Our very own Dr. Preeti Kishore provides insights into making healthier choices to start your day ! ⁦@MontefioreEndo⁩ ⁦@JacobiHosp⁩ https://t.co/oxkKMF4Joy

[Thyroid Journal @thyroidjournal]

Can we rely on negative Thyroseq molecular testing results in indeterminate nodules? What is the false negative rate/prevalence of malignancy if we took the nodules out instead of continued surveillance?

The team @Penn discusses this important issue.

https://t.co/RCvLsNF6gm

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes: @NEJM

🥸 Among persons with type 2 DM and ASCVD, CKD, or both, the use of oral semaglutide was associated with a significantly lower MACE

😱 Summary

👇👇👇

[Ranjana Srivastava @docranjana]

As an oncologist, I learn from my patients what matters most in life | Ranjana Srivastava https://t.co/bbJiPl1piV

[NEJM @NEJM]

Presented at #ATTD2025:

In the 2IQP trial involving adults with insulin-treated type 2 diabetes, automated insulin delivery resulted in lower glycated hemoglobin levels than continuous glucose monitoring alone. Read the full trial results: https://t.co/zQkwnIhV3O

@ATTDconf

[Thyroid Journal @thyroidjournal]

What is High-Grade Follicular Cell-Derived Non-Anaplastic Thyroid Carcinoma? What is included in this new pathologic diagnosis and how does its features correlate with oncologic outcome? Check out this new article from @MSKCancerCenter team in Thyroid.

https://t.co/gafYwmyQYv

[Thyroid Journal @thyroidjournal]

Is there a difference in molecular profiling of #thyroidcancers depending on their location in the thyroid? A collaboration between @Veracyte and @washumedicine in a new article @ThyroidJournal show isthmus tumors may have higher risk genetic profiles.

https://t.co/ldTuLbSIPz

[Scott Isaacs @scottisaacsmd]

The new @TheAACE dyslipidemia guideline is out. This guideline focuses on nonstatin pharmacotherapies. #WeAreAACE
https://t.co/niDKmw7LaV

[American Thyroid Association @AmThyroidAssn]

Last Chance to register for Saturday’s ATA® Alliance for Thyroid Patient Education Online Forum @ 12 PM ET. Ask questions and learn about #thyroid health!

Register Now! https://t.co/RQaQO6sJKW

@GDATF @ThyCaInc @thancfoundation @ThyroidFed @bitemecancerorg @checkyourneck

[American Thyroid Association @AmThyroidAssn]

🏆✨One week left to submit nominations! 🏆✨
Do you know an exceptional individual or team transforming the landscape of thyroid research and care? This is your chance to recognize their hard work and dedication!

👉 Award Nominations Deadline 2/2/25: https://t.co/BJrQFCH62J

[Clinical Thyroidology @clinicalthyroid]

Thyroid nodules in the #thyroid isthmus are not like the others? Perspective by @DrAKotwal reviews new data in @thyroidjournal on notable differences.

https://t.co/bylUxxg9th

#thyroidcytology #molecular #medtwitter #endotwitter #thyroidcancer #thyroidnodules